Molnupiravir | CAS 2492423-29-5 | USP/EP-Certified Antiviral API for COVID-19 Treatment?
?Google Keywords?: Molnupiravir bulk supplier, antiviral API for COVID-19, USP/EP-certified Molnupiravir, RNA mutagen drug

?? ?Product Overview?

Molnupiravir (CAS 2492423-29-5) is a broad-spectrum antiviral nucleoside analog approved for the treatment of mild-to-moderate COVID-19. It acts by inducing RNA mutagenesis in viral replication, effectively reducing viral load and transmission?12. Widely used in clinical and research settings, it is formulated as a white crystalline powder for oral administration?14.

?? ?Key Advantages?

• ?High Purity?: ≥98% HPLC purity compliant with ?USP/EP standards?, ensuring pharmaceutical-grade quality?12.

• ?Bulk Customization?: Available in 1g–25kg batches with COA, MSDS, and stability data for seamless integration into drug formulations?12.

• ?Solubility?: Optimized for DMSO solubility (≥20 mg/mL) to support preclinical and clinical studies?36.

?? ?Applications?

• ?COVID-19 Therapy?: First-line oral treatment for reducing symptom severity and hospitalization rates?13.

• ?Antiviral Drug Development?: Key reference standard for RNA virus-targeted drug discovery?24.

• ?Research?: Mechanistic studies on viral mutagenesis and resistance profiling?35.

?? ?Quality Compliance?

• Certified under ?USP/EP guidelines? with residual solvents <10 ppm and heavy metals <20 ppm?25.

• Stability tested for 24 months when stored at -20°C in airtight, light-protected packaging?24.

?? ?Market Trends?

The global antiviral drug market is projected to grow at ?7.8% CAGR (2025-2030)?, driven by persistent demand for COVID-19 therapeutics. Molnupiravir’s oral bioavailability and rapid action solidify its role in pandemic preparedness?13.